Since HIF2α was constitutively expressed we focused on altering the exogenous expression of prolyl-4-hydroxylase domain-3 (PHD3), a presumptive tumor suppressor gene and the primary regulator of HIF2α degradation (21). The gene discussed is EPAS1; the disease is neoplasm.